A study looking at pazopanib after chemotherapy in people with advanced non small cell lung cancer (MAPPING - EORTC 08092)

Cancer type:

Lung cancer
Non small cell lung cancer

Status:

Results

Phase:

Phase 3

This study looked at pazopanib after chemotherapy for non small cell lung cancer that had spread. This study was supported by Cancer Research UK.

More about this trial

If you have advanced non small cell lung cancer, you may have chemotherapy to help control symptoms and improve your quality of life. Doctors are also looking into controlling the cancer for longer by giving regular doses of a particular drug as a follow up to the main treatment. This is called maintenance treatment. 

Pazopanib is a type of biological therapy. It is a cancer growth blocker. It stops signals that cancers use to divide and grow. We know from research that it has helped lung cancers to shrink when given before surgery.

This study looked at having pazopanib after chemotherapy in people who have advanced non small cell lung cancer. 

The aim of the study was to find out if pazopanib can control the cancer for longer after chemotherapy.

Summary of results

The trial team found that having pazopanib after chemotherapy wasn’t a useful treatment for people with advanced non small lung cancer.

The people taking part were put into 1 of 2 groups at random.

  • 50  people had pazopanib
  • 52 people had the dummy drug (placebo)

The researchers looked at the early results of the first 102 people who took part. They looked at the average length of time people lived without any signs of their disease getting worse. Researchers call this progression free survival. They found that on average, this was

  • Just over 4 months in the people who had pazopanib
  • Just over 3 months in the people who had the dummy drug.

The research team had planned to recruit more people but based on these results, the trial team found that the treatment hadn’t worked as well as they had hoped. They decided it was best not to recruit any more people.

The main side effects of pazopanib were mild and included

  • High blood pressure
  • A drop in the number of white blood cells
  • A raised level of an enzyme in the liver called ALT

The trial team concluded that having pazopanib after chemotherapy didn’t control the cancer for longer. They say that pazopanib couldn’t be looked at in future trials for this group of people without looking at biomarkers. 

We have based this summary on information from the research team. The information they sent us has been reviewed by independent specialists (peer reviewed) and published in a medical journal. The figures we quote above were provided by the trial team who did the research. We have not analysed the data ourselves.

Recruitment start:

Recruitment end:

How to join a clinical trial

Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Chief Investigator

Dr Mary O'Brien

Supported by

Cancer Research UK
European Organisation for Research and Treatment of Cancer (EORTC)
GlaxoSmithKline (GSK)
NIHR Clinical Research Network: Cancer

Other information

This is Cancer Research UK trial number CRUKE/11/026

Questions about cancer? Contact our information nurses

Freephone 0808 800 4040

Last review date

CRUK internal database number:

Oracle 8281

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Around 1 in 5 people take part in clinical trials

3 phases of trials

Around 1 in 5 people diagnosed with cancer in the UK take part in a clinical trial.

Last reviewed:

Rate this page:

No votes yet
Thank you!
We've recently made some changes to the site, tell us what you think

Share this page